Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00640978 · ClinicalTrials.gov registry record · Phase 2
Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00640978: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00640978 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00640978, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of RAD001 and erlotinib hydrochloride can slow the growth of advanced pancreatic cancer. The safety of this drug combination will also be studied. Primary Objectives: -Determine the overall survival (OS) at 6 months of the combination of erlotinib and RAD001 in patients who have received previous treatment for advanced pancreatic cancer. Secondary Objectives: * Determine the progression-free survival (PFS). * Determine the response rate (RR).
Interventions
- DRUG Erlotinib
- DRUG RAD001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00640978
The ClinicalTrials.gov registry entry for NCT00640978 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Erlotinib is the first listed.
NCT00640978 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00640978 about?
NCT00640978 is a clinical study titled "Erlotinib and RAD001 (Everolimus) in Patients With Previously Treated Advanced Pancreatic Cancer". The goal of this clinical research study is to learn if the combination of RAD001 and erlotinib hydrochloride can slow the growth of advanced pancreatic cancer. The safety of this drug combination will also be studied. Primary Objectives: -Determine the overall survival (OS) at 6 months of the com...
What is the current status of trial NCT00640978?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2008-03. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00640978?
The interventions under investigation include: Erlotinib (DRUG), RAD001 (DRUG).
Who is sponsoring clinical trial NCT00640978?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.